# OnCo record alk-positive-anaplastic-large-cell-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "alk-positive-anaplastic-large-cell-lymphoma" ;
  schema:name "ALK-positive anaplastic large cell lymphoma"@en ;
  schema:alternateName "ALK-positive ALCL"@en, "ALK+ ALCL"@en, "Anaplastic large cell lymphoma, ALK-positive"@en, "ALK-positive anaplastic large-cell lymphoma"@en, "Systemic ALK-positive anaplastic large cell lymphoma"@en ;
  schema:description "An aggressive T-cell lymphoma, mostly of children and young adults, whose cells carry a broken ALK gene and a protein called CD30 on the surface. Despite looking alarming down the microscope it is the T-cell lymphoma most often cured, and both of its markers are things that drugs can aim at."@en ;
  schema:url <https://onco.cc/cancers/alk-positive-anaplastic-large-cell-lymphoma/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Anaplastic_large-cell_lymphoma> ;
  schema:citation <https://doi.org/10.1038/s41375-022-01620-2>, <https://doi.org/10.1182/blood.2022015851>, <https://doi.org/10.1016/j.annonc.2021.12.002>, <https://doi.org/10.1038/bjc.2015.94>, <https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq> ;
  onco:tag "heme", "lymphoma", "subtype-page" ;
  onco:related <https://onco.cc/cancers/alk-negative-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/primary-cutaneous-anaplastic-large-cell-lymphoma/>, <https://onco.cc/cancers/breast-implant-associated-alcl/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/adc/> ;
  onco:targets <https://onco.cc/targets/alk/>, <https://onco.cc/targets/cd30/> ;
  onco:drugs <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:terms <https://onco.cc/terms/lymphoma-classification-2022/>, <https://onco.cc/terms/lymphoma-b-versus-t-cell/>, <https://onco.cc/terms/lymphoma-pit-score/>, <https://onco.cc/terms/ipi-score/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/> ;
  onco:trials <https://onco.cc/trials/echelon-2/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/alk/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/trials/echelon-2/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/terms/lymphoma-tx-regimen-alphabet/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/lymphoma-tx-transplant-role/>, <https://onco.cc/targets/alk/> .